NASH is a worldwide epidemic disease affecting over 115 million people. Still, NASH remains an underdiagnosed and consequently an underreported disease. Untreated NASH may lead to cirrhosis, liver cancer and liver transplantation.
Our mission
The Swiss NASH Foundation is a non-for-profit organization committed to the dissemination of knowledge and raising of awareness about NASH. Through funding cutting edge research projects and increasing the knowledge and awareness about NASH, the foundation aims at contributing to treatment discovery as well as improving the patients’ quality of life.
Our history
In a joint effort to tackle the increasing prevalence and burden of NASH, scientific experts and the leading pharmaceutical companies: Gilead, Allergan, Genfit and Intercept have joined forces to establish The Swiss NASH Foundation.
Our vision
Prevent, diagnose and cure NASH.
Find out more
Swiss NASH Foundation: Mission and goals
News
- Personalized MASLD Diagnosis: Tailoring Thresholds to Improve AccuracyAsk the author session with Dr. Yasaman Vali A recent publication entitled “Precision in Liver Diagnosis: Varied accuracy across subgroups on the need for viable… Read more: Personalized MASLD Diagnosis: Tailoring Thresholds to Improve Accuracy
- Decoding MASLD: Uncovering Distinct Metabolic Subtypes for Targeted TreatmentIn a recent “Ask the Author” session, Professor Stefano Romeo discussed his groundbreaking work on data-driven cluster analysis to identify distinct types of metabolic dysfunction… Read more: Decoding MASLD: Uncovering Distinct Metabolic Subtypes for Targeted Treatment
- Entretien exclusif avec la Professeure Maru Rinella sur le resmetirom : Perspectives pour les praticiens en SuisseDécouvrez les dernières avancées dans le traitement de la stéatose hépatique non alcoolique (NASH) avec le resmetirom ! La Professeure Mary Rinella, experte renommée de… Read more: Entretien exclusif avec la Professeure Maru Rinella sur le resmetirom : Perspectives pour les praticiens en Suisse
Living with NASH
Non-alcoholic steatohepatitis (NASH) is the consequence of abnormal fat accumulation in the liver leading to liver inflammation and damage. It is the most severe form of non-alcoholic liver disease (NAFLD), commonly called “fatty liver”. NASH is a worldwide epidemic disease affecting over 115 million people.
Still, NASH remains an under-diagnosed and consequently an underreported disease.
Many people live with NASH without knowing that they have a liver disease. The quality of life of these persons might be reduced due to their liver condition. Lifestyles can do a lot to improve NASH.
But changes in diet habits, regular physical activity are measures which can improve if not cure NASH.
